Lu Xie

1.6k total citations · 1 hit paper
56 papers, 1.2k citations indexed

About

Lu Xie is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology. According to data from OpenAlex, Lu Xie has authored 56 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 14 papers in Rheumatology. Recurrent topics in Lu Xie's work include Sarcoma Diagnosis and Treatment (50 papers), Bone Tumor Diagnosis and Treatments (13 papers) and Vascular Tumors and Angiosarcomas (11 papers). Lu Xie is often cited by papers focused on Sarcoma Diagnosis and Treatment (50 papers), Bone Tumor Diagnosis and Treatments (13 papers) and Vascular Tumors and Angiosarcomas (11 papers). Lu Xie collaborates with scholars based in China, United States and Ethiopia. Lu Xie's co-authors include Jie Xu, Wei Guo, Tingting Ren, Yi Huang, Chenglong Chen, Wei Guo, Tao Ji, Wei Guo, Xin Sun and Taiqiang Yan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lu Xie

54 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

2020 377 citations Lu Xie, Jie Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lu Xie China	15	626	438	433	275	190	56	1.2k
Paolo Cotzia United States	17	439 0.7×	363 0.8×	364 0.8×	272 1.0×	149 0.8×	34	1.1k
Hongying Zhang China	20	751 1.2×	368 0.8×	402 0.9×	285 1.0×	323 1.7×	83	1.3k
Tomoya Matsunobu Japan	18	482 0.8×	257 0.6×	508 1.2×	98 0.4×	220 1.2×	54	1.1k
Robert Nakayama Japan	21	829 1.3×	496 1.1×	697 1.6×	263 1.0×	303 1.6×	82	1.6k
Changye Zou China	17	555 0.9×	311 0.7×	265 0.6×	136 0.5×	218 1.1×	48	1.1k
Sara Cresta Italy	20	461 0.7×	597 1.4×	422 1.0×	193 0.7×	205 1.1×	55	1.3k
Silvia Brich Italy	18	746 1.2×	468 1.1×	276 0.6×	149 0.5×	204 1.1×	44	1.1k
Sebastian Dorin Asaftei Italy	9	535 0.9×	328 0.7×	252 0.6×	166 0.6×	129 0.7×	27	793
Stine H. Kresse Norway	21	443 0.7×	350 0.8×	877 2.0×	604 2.2×	78 0.4×	30	1.5k

Countries citing papers authored by Lu Xie

Since Specialization

Citations

This map shows the geographic impact of Lu Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Xie more than expected).

Fields of papers citing papers by Lu Xie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Xie. The network helps show where Lu Xie may publish in the future.

Co-authorship network of co-authors of Lu Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Xie. A scholar is included among the top collaborators of Lu Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Xie. Lu Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pan, Minggui, et al.. (2024). Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers. Journal of Hematology & Oncology. 17(1). 124–124. 3 indexed citations

Xie, Lu, Xin Sun, Jie Xu, et al.. (2024). The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma. BMC Cancer. 24(1). 172–172. 1 indexed citations

Zhao, Fen, et al.. (2024). Trends and future directions of autophagy in osteosarcoma: A bibliometric analysis. Open Medicine. 19(1). 20241080–20241080. 1 indexed citations

Xu, Jie, Lu Xie, Xin Sun, et al.. (2023). Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. Clinical Cancer Research. 29(6). 1040–1046. 7 indexed citations

Shen, Jingnan, Xianbiao Xie, Lu Xie, et al.. (2023). ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.. Journal of Clinical Oncology. 41(16_suppl). 11530–11530. 1 indexed citations

Xie, Lu, Zhenyu Cai, Hezhe Lu, et al.. (2023). Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung. Heliyon. 9(5). e15527–e15527. 2 indexed citations

Xie, Lu, Xin Liang, Jie Xu, et al.. (2023). Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02). BMC Cancer. 23(1). 868–868. 8 indexed citations

Liu, Jiayong, Tian Gao, Shu Li, et al.. (2022). Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma. Clinical Cancer Research. 28(16). 3473–3479. 29 indexed citations

Sun, Xin, Jie Xu, Lu Xie, & Wei Guo. (2022). Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma. International Journal of General Medicine. Volume 15. 7581–7591. 7 indexed citations

10.

Liang, Haijie, Wei Guo, Xiaodong Tang, et al.. (2021). Venous Tumor Thrombus in Primary Bone Sarcomas in the Pelvis. Journal of Bone and Joint Surgery. 103(16). 1510–1520. 9 indexed citations

11.

Ji, Tao, Junying Li, Jie Xu, et al.. (2021). Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma. Cancer Management and Research. Volume 13. 5101–5111. 4 indexed citations

12.

Xie, Lu, Jie Xu, Wei Guo, et al.. (2021). Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience. Frontiers in Oncology. 11. 696865–696865. 6 indexed citations

13.

Xie, Lu, Jie Xu, Xin Sun, et al.. (2020). <p>Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study</p>. Cancer Management and Research. Volume 12. 3513–3525. 11 indexed citations

14.

Xie, Lu, Jie Xu, Xin Sun, et al.. (2020). 1646P Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study. Annals of Oncology. 31. S984–S984. 1 indexed citations

15.

Xie, Lu, Jie Xu, Xiaodong Tang, et al.. (2019). <p>Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years</p>. Cancer Management and Research. Volume 11. 7183–7195. 3 indexed citations

16.

Xie, Lu, Jie Xu, Xin Sun, et al.. (2018). Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. The Oncologist. 24(7). e542–e550. 94 indexed citations

17.

Xu, Jie, Wei Guo, & Lu Xie. (2018). Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?. BMC Cancer. 18(1). 987–987. 16 indexed citations

18.

Xu, Jie, Lu Xie, & Wei Guo. (2018). PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy. SHILAP Revista de lepidopterología. 8(1). 15–15. 32 indexed citations

19.

Li, Dasen, Lu Xie, Wei Guo, et al.. (2018). Extra-articular resection is a limb-salvage option for sarcoma involving the hip joint. International Orthopaedics. 42(3). 695–703. 11 indexed citations

20.

Xu, Jie, Dasen Li, Lu Xie, Shun Tang, & Wei Guo. (2015). Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years. PLoS ONE. 10(4). e0122216–e0122216. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact